<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279616</url>
  </required_header>
  <id_info>
    <org_study_id>09-00383</org_study_id>
    <nct_id>NCT01279616</nct_id>
  </id_info>
  <brief_title>A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease</brief_title>
  <official_title>A Pilot Study of an Immunosuppressive and Myeloablative Preparative Regimen for Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Severe Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Majority of patients who are eligible for allogeneic HSCT for cure of severe sickle cell
      disease lack a matched family donor. This study aims for cure of sickle cell disease by
      performing unrelated donor (outside family) allogeneic HSCT. Donors or unrelated cord blood
      units will be selected from the NMDP database. It is designed to estimate the safety of a
      novel reduced toxicity, yet an immunosuppressive and myeloablative preparative regimen. This
      is meant for patients &lt;21 years old who have severe complications from sickle cell and do not
      have matched sibling donors in the family to undergo stem cell transplant. Patients will
      undergo transplant using unrelated donor stem cells after receiving the protocol therapy.
      They will be followed for 1 year to monitor for engraftment of donor cells and complications
      like graft versus host disease (GVHD), infections and death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this pilot study is to determine the safety and feasibility of the
      preparative regimen for HSCT using a novel reduced toxicity regimen for stem cell transplant
      with unrelated donors. Analysis will be geared to confirm if the study regimen, followed by
      an appropriately HLA-matched unrelated donor (MUD)or unrelated cord blood HSCT, can lead to
      durable donor engraftment with reasonable toxicity, inhibiting sickle erythropoiesis and
      limiting disease related organ toxicity in patients who are at high risk for morbidity and
      mortality associated with sickle cell disease (SCD).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI moving to a different institution.
  </why_stopped>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Event-free survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem cell infusion on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine monophosphate</intervention_name>
    <description>180 mg/m2 over 6 days.</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 on day -13 and day -3</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>AUC 1000-1200 microM.mt</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <other_name>busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>2.5 mg/kg for 3 days</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg on day +3</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>15 mg/kg q 8 hours</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <other_name>MMF, Cell-cept.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>0.03 mg/kg /d</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <other_name>FK-506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must have sickle cell disease (genotype Hb SS or Sß° thalassemia), AND must have 1
        or more of the following clinical complications related to Sickle cell disease:

          1. A clinically significant neurologic event (stroke) or any neurologic defect lasting
             &gt;24 hours, that is accompanied by an infarct on cerebral MRI.

          2. Minimum of two episodes of acute chest syndrome (defined as new pulmonary alveolar
             consolidation involving at least 1 complete lung segment associated with acute
             symptoms including fever, chest pain, tachypnea, wheezing or cough) despite adequate
             supportive care measures (example: asthma therapy, hydroxyurea).

          3. History of severe pain episodes defined as 3 or more severe pain events per year in
             the 2 years prior to enrollment despite adequate supportive care measures and
             hydroxyurea trial (i.e. Hydroxyurea non-responders). Pain may occur in typical sites
             associated with vaso-occlusive painful events and cannot be explained by causes other
             than vaso-occlusion mediated by sickle cell disease.

          4. Recurrent priapism.

          5. Osteo-necrosis of multiple joints

          6. Evidence of Pulmonary Hypertension as evidenced by Tricuspid Regurgitation jet
             velocity (TRV) &gt; 2.5 m/s on Echocardiogram.

          7. Red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy.

        Exclusion Criteria:

          1. Invasive bacterial, viral or fungal infections within 1 month prior to starting
             conditioning therapy.

          2. Female patients who are Pregnant (Beta HCG +) or breastfeeding.

          3. HIV positive patients.

          4. Patients with HLA-matched related family donors are not eligible for this study.

          5. Prior myeloablative allogeneic HCT.

          6. Patients on chronic transfusion therapy for ≥ 1 year with evidence of cirrhosis of
             liver on biopsy

          7. Any significant concurrent disease, illness, severe cognitive delay or psychiatric
             disorder that would compromise patient safety or compliance, interfere with consent,
             study participation, follow up, or interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Soni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <results_first_submitted>February 21, 2019</results_first_submitted>
  <results_first_submitted_qc>April 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2019</results_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell</keyword>
  <keyword>stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>Drug: Fludarabine monophosphate 180 mg/m2 over 6 days.
Drug: Rituximab 375 mg/m2 on day -13 and day -3 Other Names: •Rituxan
Drug: Busulfan AUC 1000-1200 microM.mt Other Names: •busulfex
Drug: ATG 2.5 mg/kg for 3 days Other Names: •Thymoglobulin
Drug: Cyclophosphamide 50 mg/kg on day +3 Other Names: •Cytoxan
Drug: Mycophenolate mofetil 15 mg/kg q 8 hours Other Names: •MMF, Cell-cept.
Drug: Tacrolimus 0.03 mg/kg /d Other Names: •FK-506</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>donor could not be located</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no signs of sickle cell disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No baseline data are available for this study as the study was terminated. The PI has left the institution and cannot be contacted.</population>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>Stem cell infusion on Day 0.
Fludarabine monophosphate: 180 mg/m2 over 6 days.
Rituximab: 375 mg/m2 on day -13 and day -3
Busulfan: AUC 1000-1200 microM.mt
ATG: 2.5 mg/kg for 3 days
Cyclophosphamide: 50 mg/kg on day +3
Mycophenolate mofetil: 15 mg/kg q 8 hours
Tacrolimus: 0.03 mg/kg /d</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study-Specific Measure</title>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival</title>
        <description>Event-free survival</description>
        <time_frame>1 year</time_frame>
        <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI but unsuccessful. No outcome measure data is available for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>HSCT Transplant</title>
            <description>HSCT transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Event-free survival</description>
          <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI but unsuccessful. No outcome measure data is available for the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment of first participation to study termination.</time_frame>
      <desc>The study was terminated and the PI has left the institution. The only available information is in respect to the serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>No Arm Analyzed: N/A</title>
          <description>No outcome date are available for this study as the study was terminated. The PI has left the institution and cannot be contacted.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No Outcome data are available for this study as the study was terminated. The PI has left the institution and cannot be contacted.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No outcome data are available for this study as the study was terminated. The PI has left the institution and cannot be contacted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kristy Ott</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>614-722-6313</phone>
      <email>kristy.ott@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

